Evidence map›Paper›PMID 31107726›Full record

ArticleClinical and translational gastroenterology2019

Clinical and Histologic Overlap and Distinction Among Various Hamartomatous Polyposis Syndromes.

Ophir Gilad, Guy Rosner, Naomi Fliss-Isakov, Sivan Aharon-Kaspi, Hana Strul, Nathan Gluck, Revital Kariv

Abstract read
In one paragraph

Article in Clinical and translational gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. DICER1 tumor predisposition syndrome: an evolving story initiated with the pleuropulmonary blastoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Review
  8. Small Bowel Epithelial Precursor Lesions: A Focus on Molecular Alterations.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ophir GiladDepartment of Internal Medicine, Tel Aviv Medical Center, Tel-Aviv, Israel.
Guy RosnerSackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Naomi Fliss-IsakovSackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Sivan Aharon-KaspiDepartment of Gastroenterology, Tel Aviv Medical Center, Affiliated to Sackler Medical School, Tel-Aviv University, Tel-Aviv, Israel.
Hana StrulSackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Nathan GluckSackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Revital KarivSackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHamartomatous polyposis syndromes (HPS) are rare autosomal-dominant inherited disorders associated with gastrointestinal (GI) tract and other cancers. HPS include Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS), and phosphatase and tensin homolog hamartomatous tumor syndromes (PHTS). Diagnosis, management, and outcome prediction of HPS pose a clinical challenge. To characterize genotype, phenotype, histology and outcomes of individuals with HPS.

methodsA retrospective cohort study (2004-2017) of consecutive patients that were clinically diagnosed with HPS that visited a specialized GI oncology clinic. Demographic, clinicopathological, and genetic data were obtained from medical records.

resultsFifty-two individuals from 34 families were included. Common clinical manifestations were GI bleeding (40% JPS, 23% PJS, and 25% PHTS) and bowel obstruction (46.15% PJS and 11.4% JPS). Twenty patients (38.4%) underwent surgery, 5 of whom required multiple procedures. Higher polyp burden was associated with the need for surgery (P = 0.007). Polyp histology varied widely with 69.2% of patients exhibiting histology different from the syndrome hallmark. GI cancer history was positive in 65%, 40%, and 50% of JPS, PJS, and PHTS families, respectively. Five (9.6%) patients developed cancers (one patient each had small bowel-1, colon-1, and thyroid-1, one patient had both small bowel adenocarcinoma and breast cancer, and one had both breast cancer and liposarcoma). Twenty (38.4%) patients tested positive for STK11, PTEN, SMAD4, BMPR1A, or AKT1 mutations: Sanger sequencing and multi-gene next generation sequencing panels detected mutations in 40.9% and 100% of tested cases, respectively. DISCUSSION: HPS patients present versatile phenotypes with overlapping clinical and histological characteristics. Polyp burden is associated with the need for surgery. Next-generation sequencing increases mutation detection.

Indexed as

Genetic TestingAdolescentAdultAgedBiomarkers, TumorBiopsyChildClinical Decision-MakingDNA Mutational AnalysisEndoscopy, GastrointestinalFemaleFollow-Up StudiesHamartoma Syndrome, MultipleHigh-Throughput Nucleotide SequencingHumansIntestinal PolyposisBiomarkers, Tumor

Identifiers

PMID31107726
PMCPMC6602765

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.